The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.
A new prediction model for infected pancreatic necrosis (IPN) in patients with acute pancreatitis (AP) offers a groundbreaking approach to improving patient outcomes.